
Tianjin Medical Journal ›› 2026, Vol. 54 ›› Issue (4): 358-363.doi: 10.11958/20252608
• Experimental Research • Previous Articles Next Articles
ZHAI Zhihong1(
), LI Runqi2, DU Qingqing3, QIN Wenjuan4
Received:2025-07-29
Revised:2025-10-08
Published:2026-04-15
Online:2026-04-14
ZHAI Zhihong, LI Runqi, DU Qingqing, QIN Wenjuan. Study on the preventive and therapeutic effects of grape seed proanthocyanidin extract on doxorubicin-induced chronic cardiotoxicity[J]. Tianjin Medical Journal, 2026, 54(4): 358-363.
CLC Number:
| 基因名称 | 引物序列(5′→3′) | 产物大小/bp |
|---|---|---|
| Nrf2 | 上游:TCCATTTACGGAGACCCAC | 106 |
| 下游:GTGTTGGCTGTGCTTTAGGT | ||
| HO-1 | 上游:AGCGAAACAAGCAGAACC | 191 |
| 下游:CAGCAGCTCAGGATGAGTAC | ||
| NQO1 | 上游:GAAGGGTGGAAGAAGCGT | 292 |
| 下游:TGGAACAAAGGCGAAAACT | ||
| GAPDH | 上游:CAAGTTCAACGGCACAG | 138 |
| 下游:CCAGTAGACTCCACGACAT |
Tab.1 Primer sequence for PCR
| 基因名称 | 引物序列(5′→3′) | 产物大小/bp |
|---|---|---|
| Nrf2 | 上游:TCCATTTACGGAGACCCAC | 106 |
| 下游:GTGTTGGCTGTGCTTTAGGT | ||
| HO-1 | 上游:AGCGAAACAAGCAGAACC | 191 |
| 下游:CAGCAGCTCAGGATGAGTAC | ||
| NQO1 | 上游:GAAGGGTGGAAGAAGCGT | 292 |
| 下游:TGGAACAAAGGCGAAAACT | ||
| GAPDH | 上游:CAAGTTCAACGGCACAG | 138 |
| 下游:CCAGTAGACTCCACGACAT |
| 组别 | LVEDD/mm | LVESD/mm | LVEDV/mL |
|---|---|---|---|
| Control组 | 4.22±0.87 | 2.43±0.14 | 0.32±0.08 |
| DOX组 | 6.40±0.24a | 3.38±0.14a | 0.55±0.05a |
| L-GSPE组 | 5.76±0.43a | 3.21±0.15a | 0.42±0.34b |
| M-GSPE组 | 4.98±0.60b | 2.91±0.16ab | 0.37±0.08b |
| H-GSPE组 | 4.67±0.18bc | 2.69±0.48bc | 0.36±0.03b |
| TBHQ组 | 5.46±0.22 | 3.10±0.16a | 0.41±0.29b |
| F | 7.736** | 6.548** | 5.996** |
| 组别 | LVESV/mL | LVEF | LVFS |
| Control组 | 0.06±0.03 | 0.82±0.01 | 0.45±0.02 |
| DOX组 | 0.13±0.01a | 0.56±0.05a | 0.33±0.02a |
| L-GSPE组 | 0.10±0.02 | 0.65±0.03ab | 0.35±0.04a |
| M-GSPE组 | 0.10±0.03 | 0.75±0.03abc | 0.40±0.01abc |
| H-GSPE组 | 0.08±0.02b | 0.80±0.02bc | 0.42±0.02bc |
| TBHQ组 | 0.10±0.02 | 0.71±0.01abc | 0.34±0.03a |
| F | 2.145 | 36.999** | 21.478** |
Tab.2 Comparison of echocardiographic parameters between the six groups
| 组别 | LVEDD/mm | LVESD/mm | LVEDV/mL |
|---|---|---|---|
| Control组 | 4.22±0.87 | 2.43±0.14 | 0.32±0.08 |
| DOX组 | 6.40±0.24a | 3.38±0.14a | 0.55±0.05a |
| L-GSPE组 | 5.76±0.43a | 3.21±0.15a | 0.42±0.34b |
| M-GSPE组 | 4.98±0.60b | 2.91±0.16ab | 0.37±0.08b |
| H-GSPE组 | 4.67±0.18bc | 2.69±0.48bc | 0.36±0.03b |
| TBHQ组 | 5.46±0.22 | 3.10±0.16a | 0.41±0.29b |
| F | 7.736** | 6.548** | 5.996** |
| 组别 | LVESV/mL | LVEF | LVFS |
| Control组 | 0.06±0.03 | 0.82±0.01 | 0.45±0.02 |
| DOX组 | 0.13±0.01a | 0.56±0.05a | 0.33±0.02a |
| L-GSPE组 | 0.10±0.02 | 0.65±0.03ab | 0.35±0.04a |
| M-GSPE组 | 0.10±0.03 | 0.75±0.03abc | 0.40±0.01abc |
| H-GSPE组 | 0.08±0.02b | 0.80±0.02bc | 0.42±0.02bc |
| TBHQ组 | 0.10±0.02 | 0.71±0.01abc | 0.34±0.03a |
| F | 2.145 | 36.999** | 21.478** |
| 组别 | MDA/ (μmol/L) | SOD/ (U/mL) | cTnT/ (ng/L) | BNP/ (ng/L) |
|---|---|---|---|---|
| Control组 | 5.49±0.68 | 52.66±3.85 | 53.37±4.79 | 678.21±122.68 |
| DOX组 | 11.65±0.35a | 24.70±1.00a | 131.58±16.76a | 1 629.78±43.77a |
| L-GSPE组 | 8.90±0.57ab | 28.21±2.03ab | 98.61±4.11ab | 1 369.97±137.91ab |
| M-GSPE组 | 8.33±0.75abc | 33.48±1.19abc | 82.88±8.57abc | 1 243.06±119.51abc |
| H-GSPE组 | 6.41±0.85abc | 42.23±2.09abc | 74.56±5.06abc | 1 048.78±94.94abc |
| TBHQ组 | 7.71±1.20abc | 37.51±1.25bc | 81.46±6.09abc | 1 107.62±97.37abc |
| F | 136.564** | 404.964** | 163.411** | 162.285** |
Tab.3 Comparison of serum MDA, SOD, cTnT and BNP levels between the six groups
| 组别 | MDA/ (μmol/L) | SOD/ (U/mL) | cTnT/ (ng/L) | BNP/ (ng/L) |
|---|---|---|---|---|
| Control组 | 5.49±0.68 | 52.66±3.85 | 53.37±4.79 | 678.21±122.68 |
| DOX组 | 11.65±0.35a | 24.70±1.00a | 131.58±16.76a | 1 629.78±43.77a |
| L-GSPE组 | 8.90±0.57ab | 28.21±2.03ab | 98.61±4.11ab | 1 369.97±137.91ab |
| M-GSPE组 | 8.33±0.75abc | 33.48±1.19abc | 82.88±8.57abc | 1 243.06±119.51abc |
| H-GSPE组 | 6.41±0.85abc | 42.23±2.09abc | 74.56±5.06abc | 1 048.78±94.94abc |
| TBHQ组 | 7.71±1.20abc | 37.51±1.25bc | 81.46±6.09abc | 1 107.62±97.37abc |
| F | 136.564** | 404.964** | 163.411** | 162.285** |
| 组别 | Nrf2 | HO-1 | NQO1 |
|---|---|---|---|
| Control组 | 1.00±0.18 | 0.96±0.13 | 1.00±0.08 |
| DOX组 | 0.45±0.06a | 0.74±0.04a | 0.46±0.04a |
| L-GSPE组 | 1.01±0.22b | 1.17±0.06b | 1.01±0.06b |
| M-GSPE组 | 1.20±0.18b | 1.27±0.03ab | 1.16±0.07ab |
| H-GSPE组 | 1.53±0.13abc | 1.46±0.07abc | 1.16±0.06abc |
| TBHQ组 | 1.23±0.03b | 1.12±0.09b | 0.95±0.08b |
| F | 17.098** | 30.919** | 63.830** |
Tab.4 Comparison of Nrf2, HO-1 and NQO1 protein expression in the myocardium between the six groups
| 组别 | Nrf2 | HO-1 | NQO1 |
|---|---|---|---|
| Control组 | 1.00±0.18 | 0.96±0.13 | 1.00±0.08 |
| DOX组 | 0.45±0.06a | 0.74±0.04a | 0.46±0.04a |
| L-GSPE组 | 1.01±0.22b | 1.17±0.06b | 1.01±0.06b |
| M-GSPE组 | 1.20±0.18b | 1.27±0.03ab | 1.16±0.07ab |
| H-GSPE组 | 1.53±0.13abc | 1.46±0.07abc | 1.16±0.06abc |
| TBHQ组 | 1.23±0.03b | 1.12±0.09b | 0.95±0.08b |
| F | 17.098** | 30.919** | 63.830** |
| 组别 | Nrf2 mRNA | HO-1 mRNA | NQO1 mRNA |
|---|---|---|---|
| Control组 | 0.96±0.07 | 1.05±0.14 | 1.01±0.08 |
| DOX组 | 0.65±0.08a | 0.62±0.08a | 0.67±0.09a |
| L-GSPE组 | 0.95±0.17b | 1.20±0.23b | 1.12±0.12b |
| M-GSPE组 | 1.17±0.07abc | 1.90±0.17abc | 1.43±0.24abc |
| H-GSPE组 | 1.40±0.19abc | 2.13±0.43abc | 1.72±0.21abc |
| TBHQ组 | 1.11±0.12b | 1.36±0.58b | 1.20±0.92b |
| F | 25.050** | 53.708** | 36.521** |
Tab.5 Comparison of the relative expression levels of Nrf2, HO-1 and NQO1 mRNA in myocardium between the six groups
| 组别 | Nrf2 mRNA | HO-1 mRNA | NQO1 mRNA |
|---|---|---|---|
| Control组 | 0.96±0.07 | 1.05±0.14 | 1.01±0.08 |
| DOX组 | 0.65±0.08a | 0.62±0.08a | 0.67±0.09a |
| L-GSPE组 | 0.95±0.17b | 1.20±0.23b | 1.12±0.12b |
| M-GSPE组 | 1.17±0.07abc | 1.90±0.17abc | 1.43±0.24abc |
| H-GSPE组 | 1.40±0.19abc | 2.13±0.43abc | 1.72±0.21abc |
| TBHQ组 | 1.11±0.12b | 1.36±0.58b | 1.20±0.92b |
| F | 25.050** | 53.708** | 36.521** |
| [1] | DEMPKE W R.ZIELIŃSKI, WINKLER C, et al. Anthracycline-induced cardiotoxicity-are we about to clear this hurdle?[J]. Eur J Cancer, 2023, 185:94-104. doi:10.1016/j.ejca.2023.02.019. |
| [2] | BHAGAT A, KLEINERMAN E S. Anthracycline-induced cardiotoxicity:causes,mechanisms,and prevention[J]. Adv Exp Med Biol, 2020, 1257:181-192. doi:10.1007/978-3-030-43032-0_15. |
| [3] | MATTIOLI R, ILARI A, COLOTTI B, et al. Doxorubicin and other anthracyclines in cancers:activity,chemoresistance and its overcoming[J]. Mol Aspects Med, 2023, 93:101205. doi:10.1016/j.mam.2023.101205. |
| [4] | KONG C Y, GUO Z, SONG P, et al. Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity:oxidative stress and cell death[J]. Int J Biol Sci, 2022, 18(2):760-770. doi:10.7150/ijbs.65258. |
| [5] | SHERIF A A, ABDELHALIM S Z, SALIM E I. Immunohistochemical and biochemical alterations following administration of proanthocyanidin extract in rats hepatocellula carcinoma[J]. Biomed Pharmacother, 2017, 93:1310-1319. doi:10.1016/j.biopha.2017.07.039. |
| [6] | DING Y, LI H, LI Y, et al. Protective effects of grape seed proanthocyanidins on the kidneys of diabetic rats through the Nrf2 signalling pathway[J]. Evid-based Compl Alt, 2020, 2020:5205903. doi:10.1155/2020/5205903. |
| [7] | SHI S, CHEN Y, LUO Z, et al. Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy[J]. Cell Commun Signa, 2023, 21(1):61. doi:10.1186/s12964-023-01077-5. |
| [8] | VITALE R, MARZOCCO S, POPOLO A. Role of oxidative stress and inflammation in doxorubicin-induced cardiotoxicity:a brief account[J]. Int J Mol Sci, 2024, 25(13):20. doi:10.3390/ijms25137477. |
| [9] | 王若宇, 张宇, 王佳慧, 等. 复方苦参注射液减轻肝癌大鼠5-氟尿嘧啶化疗不良反应的机制研究[J]. 天津医药, 2025, 53(1):24-29. |
| WANG R Y, ZHANG Y, WANG J H, et al. Study on the mechanism of Fu Fang Ku Shen Zhu She Ye alleviating adverse reactions of 5-fluorouracil chemotherapy in rats with liver cancer[J]. Tianjin Med J, 2025, 53(1):24-29. doi:10.11958/20241277. | |
| [10] | 吴宾, 杨自更, 金玲, 等. miRNA-381-3p/MuRF1轴对低氧性肺动脉高压小鼠心肺损伤的影响[J]. 天津医药, 2025, 53(6):571-577. |
| WU B, YANG Z G, JIN L, et al. Effect of miRNA-381-3p/MuRF1 axis on cardiopulmonary injury in mice with hypoxic pulmonary hypertension[J]. Tianjin Med J, 2025, 53(6):571-577. doi:10.11958/20251127. | |
| [11] | JOOLHARZADEH P, RODRIGUEZ M, ZAGHLOL R, et al. Recent advances in serum biomarkers for risk stratification and patient management in cardio-oncology[J]. Curr Cardiol Rep, 2023, 25(3):133-146. doi:10.1007/s11886-022-01834-x. |
| [12] | ANANTHAN K, LYON A R. The role of biomarkers in cardio-oncology[J]. J Cardiovasc Transl Res, 2020, 13(2):431-450. doi:10.1007/s12265-020-10042-3. |
| [13] | WANG Q, LI J, CHU X, et al. Potential chemoprotective effects of active ingredients in Salvia miltiorrhiza on doxorubicin-induced cardiotoxicity:a systematic review of in vitro and in vivo studies[J]. Front Cardiovasc Med, 2023, 10:1267525. doi:10.3389/fcvm.2023.1267525. |
| [14] | PEREIRA G C, PEREIRA S P, PEREIRA F B, et al. Early cardiac mitochondrial molecular and functional responses to acute anthracycline treatment in wistar rats[J]. Toxicol Sci, 2019, 169(1):137-150. doi:10.1093/toxsci/kfz026. |
| [15] | HENNINGER C, FRITZ G. Statins in anthracycline-induced cardiotoxicity:Rac and Rho,and the heartbreakers[J]. Cell Death Dis, 2018, 8(1):e2564. doi:10.1038/cddis.2016.418. |
| [16] | GUPTA M, DEY S, MARBANIANG D, et al. Grape seed extract:having a potential health benefits[J]. J Food Sci Technol, 2020, 57(4):1205-1215. doi:10.1007/s13197-019-04113-w. |
| [17] | RUAN Y, JIN Q, ZENG J, et al. Grape seed proanthocyanidin extract ameliorates cardiac remodelling after myocardial infarction through PI3K/AKT pathway in mice[J]. Front Pharmacol, 2020, 11:585984. doi:10.3389/fphar.2020.585984. |
| [18] | SUL O J, CHOI H W, OH J, et al. GSPE attenuates CSE-induced lung inflammation and emphysema by regulating autophagy via the reactive oxygen species/TFEB signaling pathway[J]. Food Chem Toxicol, 2023, 177:113795. doi:10.1016/j.fct.2023.113795. |
| [19] | 姚娟, 吴平安, 李芸, 等. Keap1-Nrf2-ARE信号通路及其激活剂的研究进展[J]. 中国药理学通报, 2019, 35(10):1342-1345. |
| YAO J, WU P A, LI Y, et al. Research progress of small molecule activators in Keap1-Nrf2-ARE signaling pathway[J]. Chin Pharmacol Bull, 2019, 35(10):1342-1345. doi:10.3969/j.issn.1001-1978.2019.10.003. | |
| [20] | HU J, GU W, MA N, et al. Leonurine alleviates ferroptosis in cisplatin-induced acute kidney injury by activating the Nrf2 signaling pathway[J]. Br J Pharmacol, 2022, 179(15):3991-4009. doi:10.1111/bph.15834. |
| [21] | CHEN Q M, MALTAGLIATI A J. Nrf2 at the heart of oxidative stress and cardiac protection[J]. Physiol Genomics, 2018, 50(2):77-97. doi:10.1152/physiolgenomics.00041.2017. |
| [22] | 李润琦, 翟志红, 杜晴晴, 等. TBHQ对阿霉素慢性心脏毒性大鼠的保护作用[J]. 山西医科大学学报, 2024, 55(7):835-841. |
| LI R Q, ZHAI Z H, DU Q Q, et al. The protective effect of TBHQ on doxorubicin-induced chronic cardiotoxicity in rats[J]. J Shanxi Med Univ, 2024, 55(7):835-841. doi:10.13753/j.issn.1007-6611.2024.07.004. | |
| [23] | SUN Y, XIU C, LIU W, et al. Grape seed proanthocyanidin extract protects the retina against early diabetic injury by activating the Nrf2 pathway[J]. Exp Ther Med, 2016, 11(4):1253-1258. doi:10.3892/etm.2016.3033. |
| [1] | LI Bo, LIN Hong, HUANG Lanying, LI Lingyu. The relationship between HMOX1 and MAPK14 with the onset and prognosis of sepsis-induced acute lung injury in children [J]. Tianjin Medical Journal, 2025, 53(10): 1052-1056. |
| [2] | WANG Ruoyu, ZHANG Yu, WANG Jiahui, ZHANG Zhanxia. Study on the mechanism of Fu Fang Ku Shen Zhu She Ye alleviating adverse reactions of 5-fluorouracil chemotherapy in rats with liver cancer [J]. Tianjin Medical Journal, 2025, 53(1): 24-28. |
| [3] | LI Min, GONG Jian, WU Weiwei, LIU Qiao. Research progress on the role of Nrf2/HO-1 pathway in psoriasis [J]. Tianjin Medical Journal, 2024, 52(5): 552-556. |
| [4] | YANG Yuan, SONG Shuang, CHEN Rong, LIU Yonglian, LIU Chunyan. Study of ginsenoside Rg1 antagonizes sodium arsenite-induced nephrotoxicity in C57BL/6 mice [J]. Tianjin Medical Journal, 2023, 51(8): 820-824. |
| [5] | ZHAI Xinxiang, DONG Hui, WANG Jing, WANG Yongxiang. Study on the protective mechanism of astragalus polysaccharides on functional activity of osteoblasts in ovariectomy rats [J]. Tianjin Medical Journal, 2022, 50(3): 265-269. |
| [6] | CHEN Li, MA Yali, LI Benliang. The effects of exogenous hydrogen sulfide on cognitive function and intestinal barrier function through Nrf2/ARE/HO-1 pathway in schizophrenic rats [J]. Tianjin Medical Journal, 2022, 50(2): 143-149. |
| [7] | MA Zhi, WANG Xinshuang, LIU Yue, WEI Liping, QI Xin. The protective mechanism of differential isomers of glycyrrhetinic acid on cisplatin-induced H9c2 cardiomyocyte injury [J]. Tianjin Medical Journal, 2022, 50(12): 1264-1269. |
| [8] | Effects of miR-a on doxorubicin resistance in breast cancer by targeting Akt/Bcl-. Effects of miR-34a on doxorubicin resistance in breast cancer by targeting Akt/Bcl-2 [J]. Tianjin Medical Journal, 2022, 50(1): 41-45. |
| [9] | YI Na, YUAN Li-li. Effects and mechanism of BMAL1 on H2O2-induced H9C2 cardiomyocyte injury [J]. Tianjin Medical Journal, 2021, 49(8): 791-795. |
| [10] | LI Yuan-yang, , ZHOU Xiang-zhong, LEI Xiang-hong, ZHANG Yu-fan, , XU Yue, , WEI Li-ping△. The experimental study on astragaloside Ⅳ regulating mitochondrial autophagy to reduce myocardial toxicity induced by 5-Fu in aging rats [J]. Tianjin Medical Journal, 2021, 49(4): 378-384. |
| [11] | HU Dan, XIAO He-liu, YU Qin△. MCP-1 participates in the protective effect of valsartan on doxorubicin induced myocardial injury#br# [J]. Tianjin Medical Journal, 2020, 48(8): 715-719. |
| [12] | ZHAN Qian, DU Li-jun, DAI Xi, YUAN Jing, LIU Ben, WANG Rong-li△. Effects of heme oxygenase -1 on MUC5AC and IL-25 in asthmatic mice [J]. Tianjin Medical Journal, 2020, 48(10): 952-956. |
| [13] | GAO Fei, ZENG Rui-xia, JIANG Dong. Effects of TFPGL on Nrf2/HO-1 signaling pathway in kidneys of diabetic rats [J]. Tianjin Medical Journal, 2019, 47(9): 928-931. |
| [14] | WANG Dan-dan, TAO Gui-zhou, HUANG Jian-hua, LIU Hua. Adenoviral vector mediated C/ebp delta gene improves the function of ischemic heart in mice [J]. Tianjin Medical Journal, 2019, 47(2): 131-135. |
| [15] | YANG Li-jun, CHU Li-ping, WANG Jing, REN Chun-hua, WANG Zhong-qiang, HUANG Fan. Preparation of doxorubicin modified silver nanoparticle and its anti-tumor activity in vitro [J]. Tianjin Med J, 2018, 46(5): 499-504. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||